Johnson & Johnson‘s (NYSE:JNJ) move to ditch its DePuy trauma business mollified EuroZone anti-trust regulators enough to win their approval for its $21.3 billion buyout of Synthes Inc.
EU clears J&J’s $21B Synthes buyout | Wall Street Beat
Linden Capital Partners
Bioject CEO departs after layoffs | Personnel Moves
Needle-free drug delivery company Bioject Medical Technologies (OTC:BJCT) announced the departure of its president & CEO "for cost-cutting reasons" on the heels of major cuts to its workforce.
Ralph Makar, who took the corner office at Bioject four years ago, ceded his role to board member Mark Logomasini, who will serve as interim president & CEO, effective immediately.
Private equity experts: Sour economy cools white-hot med-tech LBO market
The souring economy put a dent in the white-hot leveraged buyout market for the med-tech industry, a panel of fund managers said yesterday at the AdvaMed 2011 conference in Washington.
The European banks crisis, an uncertain regulatory environment in the U.S. and a looming new tax on medical devices all have mixed into a toxic stew that’s choking the LBO market, which had surged back since the economic slump in 2009.
